Top

Published in:

01-05-2017 | Magnetic Resonance

Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes

Authors: Qirui Zhang, Fang Yang, Zheng Hu, Zhiqiang Zhang, Qiang Xu, Mantini Dante, Han Wu, Zhipeng Li, Qian Li, Kai Li, Guangming Lu

Published in: European Radiology | Issue 5/2017

Abstract

Objectives

Our aim was to investigate regional difference in brain activities in response to antiepileptic drug (AED) medications in benign epilepsy with central-temporal spikes (BECTS) using resting-state functional magnetic resonance imaging (fMRI).

Methods

Fifty-seven patients with BECTS underwent resting-state fMRI scans after receiving either valproic acid (VPA) (n = 15), levetiracetam (LEV) (n = 21), or no medication (n = 21). fMRI regional homogeneity (ReHo) parameter among the three groups of patients were compared and were correlated with total doses of AED in the two medicated groups.

Results

Compared with patients on no-medication, patients receiving either VPA or LEV showed decreased ReHo in the central-temporal region, frontal cortex, and thalamus. In particular, the VPA group showed greater ReHo decrease in the thalamus and milder in cortices and caudate heads compared with the LEV group. In addition, the VPA group demonstrated a negative correlation between ReHo values in the central-temporal region and medication dose.

Conclusion

Both VPA and LEV inhibit resting-state neural activity in the central-temporal region, which is the main epileptogenic focus of BECTS. VPA reduced brain activity in the cortical epileptogenic regions and thalamus evenly, whereas LEV reduced brain activity predominantly in the cortices. Interestingly, VPA showed a cumulative effect on inhibiting brain activity in the epileptogenic regions in BECTS.

Key Points

• Regional differences in brain activity in response to different AEDs in BECTS.

• AEDs inhibit resting-state neural activity in epileptogenic and subcortical regions in BECTS.

• Valproic acid effect on the cortical epileptogenic regions and thalamus evenly.

• Levetiracetam effect seen predominantly in cortices.

• Valproic acid has a cumulative effect on inhibiting brain activity in epileptogenic regions.

Available only for authorised users

Beaussart M (1972) Benign epilepsy of children with Rolandic (centro-temporal) paroxysmal foci. A clinical entity. Study of 221 cases. Epilepsia 13(6):795–811CrossRefPubMed

Giordani B, Caveney AF, Laughrin D, Huffman JL, Berent S, Sharma U, Giles JM, Garofalo EA (2006) Cognition and behavior in children with benign epilepsy with centrotemporal spikes (BECTS). Epilepsy Res 70(1):89–94CrossRefPubMed

Stephani U (2000) Typical semiology of benign childhood epilepsy with centrotemporal spikes (BCECTS). Epileptic Disord: Int Epilepsy J Videotape 2(Suppl 1):S3–S4

Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, Lu Z, Group NS (2006) Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66(11):1654–1660CrossRefPubMed

Loscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS drugs 16(10):669–694CrossRefPubMed

Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H (2008) SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54(4):715–720CrossRefPubMed

Wandschneider B, Stretton J, Sidhu M, Centeno M, Kozak LR, Symms M, Thompson PJ, Duncan JS, Koepp MJ (2014) Levetiracetam reduces abnormal network activations in temporal lobe epilepsy. Neurology 83(17):1508–1512CrossRefPubMedPubMedCentral

Pardoe HR, Berg AT, Jackson GD (2013) Sodium valproate use is associated with reduced parietal lobe thickness and brain volume. Neurology 80(20):1895–1900CrossRefPubMedPubMedCentral

Tang Y, Yu X, Zhang X, Xia W, Wu X, Zou X, Li H, Huang X, Stefan H, Chen Q, Gong Q, Zhou D (2015) Single-dose intravenous administration of antiepileptic drugs induces rapid and reversible remodeling in the brain: Evidence from a voxel-based morphometry evaluation of valproate and levetiracetam in rhesus monkeys. Neuroscience 303:595–603CrossRefPubMed

10.

Simister RJ, McLean MA, Barker GJ, Duncan JS (2007) The effect of sodium valproate on proton MRS visible neurochemical concentrations. Epilepsy Res 74(2–3):215–219CrossRefPubMed

11.

Zeng H, Ramos CG, Nair VA, Hu Y, Liao J, La C, Chen L, Gan Y, Wen F, Hermann B, Prabhakaran V (2015) Regional homogeneity (ReHo) changes in new onset versus chronic benign epilepsy of childhood with centrotemporal spikes (BECTS): A resting state fMRI study. Epilepsy Res 116:79–85CrossRefPubMedPubMedCentral

12.

Zhong Y, Lu G, Zhang Z, Jiao Q, Li K, Liu Y (2011) Altered regional synchronization in epileptic patients with generalized tonic-clonic seizures. Epilepsy Res 97(1–2):83–91CrossRefPubMed

13.

Zang Y, Jiang T, Lu Y, He Y, Tian L (2004) Regional homogeneity approach to fMRI data analysis. Neuroimage 22(1):394–400CrossRefPubMed

14.

Tang YL, Ji GJ, Yu Y, Wang J, Wang ZJ, Zang YF, Liao W, Ding MP (2014) Altered regional homogeneity in rolandic epilepsy: a resting-state FMRI study. BioMed Res Int 2014:960395PubMedPubMedCentral

15.

Mankinen K, Long XY, Paakki JJ, Harila M, Rytky S, Tervonen O, Nikkinen J, Starck T, Remes J, Rantala H, Zang YF, Kiviniemi V (2011) Alterations in regional homogeneity of baseline brain activity in pediatric temporal lobe epilepsy. Brain Res 1373:221–229CrossRefPubMed

16.

Yang T, Fang Z, Ren J, Xiao F, Li Q, Liu L, Lei D, Gong Q, Zhou D (2014) Altered spontaneous activity in treatment-naive childhood absence epilepsy revealed by Regional Homogeneity. J Neurol Sci 340(1–2):58–62CrossRefPubMed

17.

Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51(4):676–685CrossRefPubMed

18.

Poline JB, Worsley KJ, Evans AC, Friston KJ (1997) Combining spatial extent and peak intensity to test for activations in functional imaging. Neuroimage 5(2):83–96CrossRefPubMed

19.

Lerch JP, Worsley K, Shaw WP, Greenstein DK, Lenroot RK, Giedd J, Evans AC (2006) Mapping anatomical correlations across cerebral cortex (MACACC) using cortical thickness from MRI. Neuroimage 31(3):993–1003CrossRefPubMed

20.

Jokeit H, Okujava M, Woermann FG (2001) Carbamazepine reduces memory induced activation of mesial temporal lobe structures: a pharmacological fMRI-study. BMC Neurol 1:6CrossRefPubMedPubMedCentral

21.

Szaflarski JP, Allendorfer JB (2012) Topiramate and its effect on fMRI of language in patients with right or left temporal lobe epilepsy. Epilepsy Behav 24(1):74–80CrossRefPubMedPubMedCentral

22.

Koepp MJ (2011) Gender and drug effects on neuroimaging in epilepsy. Epilepsia 52(Suppl 4):35–37CrossRefPubMed

23.

de Saint-Martin A, Petiau C, Massa R, Maquet P, Marescaux C, Hirsch E, Metz-Lutz MN (1999) Idiopathic rolandic epilepsy with "interictal" facial myoclonia and oromotor deficit: a longitudinal EEG and PET study. Epilepsia 40(5):614–620CrossRefPubMed

24.

Archer J, Briellman R, Abbott D, Syngeniotis A, Wellard RM, Jackson G (2003) Benign Epilepsy with Centro-temporal Spikes: Spike Triggered fMRI Shows Somato-sensory CortexActivity. Epilepsia 44(2):200–204CrossRefPubMed

25.

Boor S, Vucurevic G, Pfleiderer C, Stoeter P, Kutschke G, Boor R (2003) EEG-related Functional MRI in Benign Childhood Epilepsy with CentrotemporalSpikes. Epilepsia 44(5):688–692CrossRefPubMed

26.

Boor R, Jacobs J, Hinzmann A, Bauermann T, Scherg M, Boor S, Vucurevic G, Pfleiderer C, Kutschke G, Stoeter P (2007) Combined spike-related functional MRI and multiple source analysis in the non-invasive spike localization of benign rolandic epilepsy. Clin Neurophysiol 118(4):901–909CrossRefPubMed

27.

Masterton RA, Harvey AS, Archer JS, Lillywhite LM, Abbott DF, Scheffer IE, Jackson GD (2010) Focal epileptiform spikes do not show a canonical BOLD response in patients with benign rolandic epilepsy (BECTS). Neuroimage 51(1):252–260CrossRefPubMed

28.

Norden AD, Blumenfeld H (2002) The role of subcortical structures in human epilepsy. Epilepsy Behav: E&B 3(3):219–231CrossRef

29.

Zhang ZQ, Liao W, Chen HF, Mantini D, Ding JR, Xu Q, Wang ZG, Yuan CP, Chen GH, Jiao Q, Lu GM (2011) Altered functional-structural coupling of large-scale brain networks in idiopathic generalized epilepsy. Brain: J Neurol 134(Pt 10):2912–2928CrossRef

30.

Liao W, Zhang Z, Mantini D, Xu Q, Ji GJ, Zhang H, Wang J, Wang Z, Chen G, Tian L, Jiao Q, Zang YF, Lu G (2014) Dynamical intrinsic functional architecture of the brain during absence seizures. Brain Struct Funct 219(6):2001–2015CrossRefPubMed

31.

Jang JW, Youn YC, Seok JW, Ha SY, Shin HW, Ahan SW, Park KY, Kwon OS (2011) Hypermetabolism in the left thalamus and right inferior temporal area on positron emission tomography-statistical parametric mapping (PET-SPM) in a patient with Charles Bonnet syndrome resolving after treatment with valproic acid. J Clin Neurosci: Off J Neurosurg Soc Aust 18(8):1130–1132CrossRef

32.

Gaillard WD, Zeffiro T, Fazilat S, DeCarli C, Theodore WH (1996) Effect of valproate on cerebral metabolism and blood flow: an 18F-2-deoxyglucose and 15O water positron emission tomography study. Epilepsia 37(6):515–521CrossRefPubMed

33.

Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P (2000) Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41(9):1179–1186CrossRefPubMed

34.

Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U, Levetiracetam NSG (2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69(18):1751–1760CrossRefPubMed

35.

Fattore C, Boniver C, Capovilla G, Cerminara C, Citterio A, Coppola G, Costa P, Darra F, Vecchi M, Perucca E (2011) A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 52(4):802–809CrossRefPubMed

36.

Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101(26):9861–9866CrossRefPubMedPubMedCentral

37.

Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A 96(26):15268–15273CrossRefPubMedPubMedCentral

38.

Crevecoeur J, Foerch P, Doupagne M, Thielen C, Vandenplas C, Moonen G, Deprez M, Rogister B (2013) Expression of SV2 isoforms during rodent brain development. BMC Neurosci 14:87CrossRefPubMedPubMedCentral

39.

Shiraishi H, Haginoya K, Nakagawa E, Saitoh S, Kaneko Y, Nakasato N, Chan D, Otsubo H (2014) Magnetoencephalography localizing spike sources of atypical benign partial epilepsy. Brain Dev 36(1):21–27CrossRefPubMed

40.

Davis R, Peters DH, McTavish D (1994) Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47(2):332–372CrossRefPubMed

41.

Calandre EP, Dominguez-Granados R, Gomez-Rubio M, Molina-Font JA (1990) Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. Acta Neurol Scand 81(6):504–506CrossRefPubMed

42.

Umka J, Mustafa S, ElBeltagy M, Thorpe A, Latif L, Bennett G, Wigmore PM (2010) Valproic acid reduces spatial working memory and cell proliferation in the hippocampus. Neuroscience 166(1):15–22CrossRefPubMed

43.

Senturk V, Goker C, Bilgic A, Olmez S, Tugcu H, Oncu B, Atbasoglu EC (2007) Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord 9(Suppl 1):136–144CrossRefPubMed

44.

Cysique LA, Maruff P, Brew BJ (2006) Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC Neurol 6:42CrossRefPubMedPubMedCentral

45.

Koo DL, Hwang KJ, Kim D, Kim YJ, Kim JY, Shin W, Kim MR, Joo EY, Lee JM, Hong SB (2013) Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients. Eur Neurol 70(1–2):88–94CrossRefPubMed

46.

Cho JR, Koo DL, Joo EY, Yoon SM, Ju E, Lee J, Kim DY, Hong SB (2012) Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naive epilepsy patients. Clin Neurophysiol: Off J Int Fed Clin Neurophysiol 123(5):883–891CrossRef

47.

Schiemann-Delgado J, Yang H, Loge Cde L, Stalvey TJ, Jones J, Legoff D, Mintz M (2012) A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures. J Child Neurol 27(1):80–89CrossRefPubMed

Title: Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes
Authors: Qirui Zhang
Fang Yang
Zheng Hu
Zhiqiang Zhang
Qiang Xu
Mantini Dante
Han Wu
Zhipeng Li
Qian Li
Kai Li
Guangming Lu
Publication date: 01-05-2017
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 5/2017
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-016-4531-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Key Points

Please log in to get access to this content

Other articles of this Issue 5/2017

Multicenter external validation of two malignancy risk prediction models in patients undergoing 18F-FDG-PET for solitary pulmonary nodule evaluation

MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent

Cadaver-specific CT scans visualized at the dissection table combined with virtual dissection tables improve learning performance in general gross anatomy

Abdominal aortic aneurysm follow-up by shear wave elasticity imaging after endovascular repair in a canine model

Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study

Ultrasound-guided synovial Tru-cut biopsy: indications, technique, and outcome in 111 cases